Abstract
The nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib significantly improved survival in metastatic colorectal cancer patients (mCRC). Both treatments are characterized by different treatment-related adverse events but detailed analyses of predictive side effects are rare. In this retrospective, observational, real-life study, clinical data on mCRC patients treated with trifluridine/tipiracil or regorafenib at the Medical University of Vienna, Austria and the University Hospital Zurich, Switzerland were collected. The correlation between adverse events and response or survival rates were calculated performing Fisher's exact test and log-rank test, respectively. Common adverse events of any grade included fatigue (52%), nausea/vertigo (34%), anemia (26%), and leukopenia (22%) in trifluridine/tipiracil patients and fatigue (42%), hand-foot-skin syndrome (36%) and hoarseness (34%) in patients upon regorafenib treatment. In trifluridine/tipiracil patients the prevalence of leukopenia (p = 0.044) and weight loss (p = 0.044) was prognostic, whereas leukopenia (p = 0.044) and neutropenia (p = 0.043) predicted PFS. The disease control rate was not significantly affected. In regorafenib-treated patien...Continue Reading
References
Nov 28, 2012·Lancet·Axel GrotheyUNKNOWN CORRECT Study Group
Nov 15, 2013·The Lancet Oncology·Yasuhide YamadaKenichi Sugihara
Jun 4, 2014·CA: a Cancer Journal for Clinicians·Carol E DeSantisAhmedin Jemal
Aug 5, 2014·The Lancet Oncology·Volker HeinemannSebastian Stintzing
Sep 13, 2014·Targeted Oncology·Jean-Baptiste ReyChristophe Tournigand
Sep 19, 2014·Oncology Reports·Nozomu TanakaKenichi Matsuo
Oct 23, 2014·The New England Journal of Medicine·Fotios LoupakisAlfredo Falcone
May 15, 2015·The New England Journal of Medicine·Robert J MayerUNKNOWN RECOURSE Study Group
May 20, 2015·The Lancet Oncology·Jin LiUNKNOWN CONCUR Investigators
Jan 3, 2016·Clinical Colorectal Cancer·Daisuke KotaniTakayuki Yoshino
Jun 23, 2016·OncoTargets and Therapy·Yoon Ji ChoiYeul Hong Kim
Jul 7, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemD Arnold
Aug 16, 2016·Clinical Colorectal Cancer·Satoshi HamauchiHiroya Taniguchi
Sep 28, 2016·Clinical Colorectal Cancer·Toshiki MasuishiKentaro Yamazaki
Dec 10, 2016·Lancet·Jordi BruixUNKNOWN RESORCE Investigators
Mar 6, 2017·Oncology Reports·Nao KakizawaToshiki Rikiyama
Mar 30, 2017·Cancer Treatment Reviews·Andrés PovedaUNKNOWN GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research)
Nov 21, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T YoshinoJ-Y Douillard
Nov 28, 2017·Clinical Colorectal Cancer·Ana B K AbrahaoKelvin K W Chan
Jun 27, 2018·Neoplasma·M UnseldG Prager
Sep 13, 2018·CA: a Cancer Journal for Clinicians·Freddie BrayAhmedin Jemal
Jul 3, 2019·The Lancet Oncology·Tanios S Bekaii-SaabAxel Grothey
Feb 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G ArgilesE Aranda